Featured News
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Innovator-of-Year to AMPEL
COMPANY
Dr. Amrie Grammer of AMPEL BioSolutions joins host Rich Bendis on BioTalk
CLICK TO VIEW ARTICLE & WATCH VIDEO > AMPEL BioSolutions Co-Founder and COO/CSO, Dr. Amrie Grammer guests on BioTalk to discuss building the Company in Charlottesville, VA, her work and recognition at NIH, and being a leader from the southern part of the...
Lupus Research Alliance Announces Published Data Showing Effective Approach to Drug Repositioning
New results published in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs approved for use in other diseases.
ACR Symposium Shows Need for Novel Drug Discovery Methods
In a session presented at the American College of Rheumatology and Association of Rheumatology Health Professionals annual meeting, Peter E. Lipsky, MD, discussed his efforts to further lupus treatment options.
PLATFORM
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PRODUCTS
LuGENE blood test may help personalize treatment for lupus
Ampel BioSolutions is launching LuGENE, a blood test that uses artificial intelligence (AI) to look at a patient’s gene activity and predict when lupus flares are likely to happen and which medications could be most effective to keep symptoms in check.
New Blood Test Poised to Revolutionize Care for Systemic Lupus Erythematosus
AMPEL BioSolutions announced the launch of LuGENE®, an exciting breakthrough innovation in systematic lupus erythematosus (SLE) care. LuGENE® is a new blood test designed to predict SLE flares before they happen and provide specific information about each individual’s disease abnormalities, leading to faster, evidence-based treatment.
Precision Medicine in Action: New Blood Test May Predict Lupus Flares, Eliminate Treatment Trial and Error
AMPEL BioSolutions’ LuGENE blood test may help predict lupus flares and drug targets from gene expression utilizing predictive artificial intelligence (AI).
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus. Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI.
A Chase for More Precise Brand of Medication
Well, you see, more than 95 percent Lupus patients have experienced a flare of symptoms in the last year. Hence, in response, the new LuGENE® test identifies real-time abnormalities leading to inflammation and immune system dysfunction, abnormalities that are especially targetable by medication.
LuGENE® Launches for Lupus
During this interview with Scripps News Network, Dr. Grammer explains how there is currently no way to predict flares or determine which is the most appropriate treatment for an individual lupus patient. Identifying a therapeutic regimen that stabilizes a patient’s disease course often takes several years of trial and error.
PARTNERS
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
Today AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
Krill Oil appeared to decrease Lupus disease activity in patients who were sicker at baseline (measured by the standard SLEDAI-2K greater than 9).
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
AMPEL is a Precision Health company commercializing a development pipeline of blood tests that measure dynamic RNA gene expression providing a real-time CLIA-certified report of inflammation status including drugs targets that are abnormal.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
CLICK FOR ORIGINAL ARTICLE > CHARLOTTESVILLE, Va., July 15, 2024 /PRNewswire/ -- Today AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease...
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
“Research has shown that people with lupus are at an elevated risk of inflammation and cardiovascular complications,” said Dr. Amrie Grammer
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
This study demonstrated that patients with lupus uniformly have depressed levels of omega-3 fatty acids and that Krill Oil supplementation safely returns omega-3 levels into a less risky range.